Targeted Therapy for Severe Asthma: Identifying the Right Patients (original) (raw)

IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma

Daniel Amaya

World Allergy Organization Journal, 2021

View PDFchevron_right

Can biomarkers help us hit targets in difficult-to-treat asthma?

John Upham

Respirology (Carlton, Vic.), 2017

View PDFchevron_right

A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels

Eddie McKnight

Respiratory medicine, 2018

View PDFchevron_right

Responses to biological therapies in eosinophilic severe asthma

Esozia Arroabarren

Journal of Investigational Allergology and Clinical Immunology, 2019

View PDFchevron_right

Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective

Massimo Guerriero

Journal of Investigational Allergology and Clinical Immunology, 2019

View PDFchevron_right

Refractory asthma phenotyping based on immunoglobulin E levels and eosinophilic counts: A real life study

Hani Lababidi

Respiratory Medicine, 2019

View PDFchevron_right

Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice

ioanna tsiouprou

Journal of Personalized Medicine

View PDFchevron_right

Severe Asthma and Biological Therapy: When, Which, and for Whom

Bice Ritondo

Pulmonary therapy, 2019

View PDFchevron_right

Towards clinically applicable biomarkers for asthma – An EAACI position paper

Svetlana Sergejeva

Allergy

View PDFchevron_right

Biomarkers and severe asthma: a critical appraisal

ANNA MARIA Riccio

Clinical and Molecular Allergy, 2015

View PDFchevron_right

Toward clinically applicable biomarkers for asthma: An EAACI position paper

A-c. Olin

Allergy, 2019

View PDFchevron_right

Hallmarks Cytokines on Eosinophils and Asthma Single and Synergistic Effects of Type 2

jhonatan montoya

View PDFchevron_right

Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma

Stephan Korom

The Journal of Allergy and Clinical Immunology: In Practice, 2020

View PDFchevron_right

Eosinophils Target Therapy for Severe Asthma: Critical Points

L. Brussino

BioMed Research International

View PDFchevron_right

Biologic and New Therapies in Asthma

Dennis Ledford

Immunology and allergy clinics of North America, 2017

View PDFchevron_right

Value of peripheral blood eosinophil markers to predict severity of asthma

Robert Kemp

BMC pulmonary medicine, 2016

View PDFchevron_right

Biomarkers of therapy responsiveness in asthma: pitfalls and promises

Leo Koenderman

Clinical & Experimental Allergy, 2011

View PDFchevron_right

Variability of blood eosinophil count as an asthma biomarker

Elizabeth Schwantes

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2016

View PDFchevron_right

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center

Fulvia Ribolla

Biomedicines, 2022

View PDFchevron_right

Eosinophilic bioactivities in severe asthma

Bruce Bochner

The World Allergy Organization journal, 2016

View PDFchevron_right

Variability of blood eosinophils in patients in a clinic for severe asthma

Gabriele Grunig

Clinical & Experimental Allergy, 2018

View PDFchevron_right

Antibody therapy for the management of severe asthma with eosinophilic inflammation

Ken Ohta

International Immunology, 2017

View PDFchevron_right

Validation and further insight into the International Severe Asthma Registry (ISAR) eosinophil gradient algorithm in the Wessex AsThma CoHort of difficult asthma (WATCH) using historical blood eosinophil counts and induced sputum

Mohammad Aref Kyyaly

Clinical & Experimental Allergy, 2022

View PDFchevron_right

Phenotyping severe asthma: a rationale for biologic therapy

Cristiana Stellato

Expert Review of Precision Medicine and Drug Development, 2020

View PDFchevron_right

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights

Matteo Fontana

Journal of Asthma and Allergy

View PDFchevron_right

Eosinophilic Asthma

Fozia Masood

Asthma and Lung Biology [Working Title]

View PDFchevron_right

Clinical control of asthma associates with measures of airway inflammation

Franke Volbeda

Thorax, 2013

View PDFchevron_right

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

Emílio Pizzichini

The Lancet Respiratory Medicine, 2014

View PDFchevron_right

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

Stephane Kirkesseli

New England Journal of Medicine, 2013

View PDFchevron_right

Airway Inflammatory Biomarker: Could It Tailor the Right Medications for the Right Asthmatic Patient?

Wafaa Laimon

2016

View PDFchevron_right